Oncosec Medical Inc (ONCS)

Trade ONCS now with
12/5/2019 8:47:21 AM OncoSec To Present Interim Data From KEYNOTE-890 Study Of TAVO And KEYTRUDA In Late-Stage MTNBC
11/27/2019 8:34:27 AM Alpha Wins In Nevada Court And Comments On OncoSec's Cynical Attempt To Push Through China Grand Deal
11/12/2019 8:38:40 AM OncoSec Presents Immunological Data Associated With Positive Tumor Response From TAVO KEYNOTE Studies
10/21/2019 9:03:08 AM OncoSec Provides Letter To Shareholders On Recently-Announced $30 Mln Strategic Investment
7/29/2019 8:51:08 AM Leidos Declares Quarterly Cash Dividend Of $0.34/shr, Represents $0.02 Increase; Payable Sept. 30/record Sept. 16
6/27/2019 8:38:24 AM OncoSec Gets Licensing Rights From Dana-Farber CancerInstitute To CAR T-Cell Therapies For Solid Tumor Cancers Treatment
5/29/2019 8:32:14 AM OncoSec Announces Collaboration For TAVO In Australia With Emerge Health
5/23/2019 8:33:26 AM UCSF Doses First Patient In Triple Combination Clinical Trial Of OncoSec's TAVO, Epacadostat And KEYTRUDA
5/22/2019 8:52:41 AM OncoSec Medical Prices $11 Mln Public Offering
5/21/2019 4:03:38 PM OncoSec Medical Announces Proposed Public Offering
5/20/2019 1:18:22 PM OncoSec Announces 1-for-10 Reverse Stock Split
4/23/2019 8:08:54 AM OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO, Epacadostat And KEYTRUDA In SCCHN Cancer
11/6/2018 8:10:03 AM OncoSec Reports Preliminary Data From KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial Of TAVO
10/15/2018 7:33:34 AM OncoSec Initiates KEYNOTE-890, Phase 2 Trial Of TAVO In Combination With Merck's KEYTRUDA For Late-Stage TNBC Treatment
8/6/2018 8:10:09 AM OncoSec Enters Research Collaboration Deal With UCLA And Roger Lo
7/30/2018 8:07:24 AM OncoSec Appoints Robert Ashworth As VP, Regulatory